-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the National Medical Products Administration (NMPA) of China approved teriprizumab injection (trade name: Tuoyi®) for the failure of platinum-containing chemotherapy, including neoadjuvant or adjuvant chemotherapy, for locally advanced or metastatic disease that has progressed within 12 months Treatment of sexual urothelial carcinoma.
Recently, the National Medical Products Administration (NMPA) of China approved teriprizumab injection (trade name: Tuoyi®) for the failure of platinum-containing chemotherapy, including neoadjuvant or adjuvant chemotherapy, for locally advanced or metastatic disease that has progressed within 12 months Treatment of sexual urothelial carcinoma.
Urothelial cancer has a high recurrence rate, a poor prognosis and a serious impact on the quality of life
Urothelial carcinoma (UC) is a common type of bladder cancer, accounting for more than 90% of all bladder cancer cases.
Professor Guo Jun from Peking University Cancer Hospital pointed out: “At present, the treatment methods for patients after metastasis and recurrence of urothelial cancer at home and abroad are very limited.
PD-1 immunotherapy brings new hope, benefiting more patients with urothelial cancer
PD-1 immunotherapy brings new hope, benefiting more patients with urothelial cancerTeriplizumab is a recombinant humanized anti-PD-1 monoclonal antibody injection.
It is worth noting that POLARIS-03 is the first key clinical study conducted on non-selected people with advanced urothelial cancer who have failed the first-line standard treatment in China.
Professor Huang Yiran, Renji Hospital, Shanghai Jiaotong University School of Medicine, said: “According to the published data on the efficacy of PD-1/PD-L1 in the second-line treatment of advanced urothelial carcinoma, the objective response rate is generally around 20%, with a median The overall survival period is mostly about 10 months.
